Celemics Past Earnings Performance
Past criteria checks 0/6
Celemics has been growing earnings at an average annual rate of 19.2%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been declining at an average rate of 24.6% per year.
Key information
19.2%
Earnings growth rate
19.2%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | -24.6% |
| Return on equity | -24.4% |
| Net Margin | -58.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Celemics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,578 | -3,876 | 5,629 | 1,308 |
| 31 Dec 22 | 8,729 | -4,797 | 5,548 | 2,211 |
Quality Earnings: A331920 is currently unprofitable.
Growing Profit Margin: A331920 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A331920's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A331920's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A331920 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.1%).
Return on Equity
High ROE: A331920 has a negative Return on Equity (-24.4%), as it is currently unprofitable.